Inovio Pharmaceuticals (NASDAQ:INO) Upgraded to "Hold" at Wall Street Zen

Key Points

• Wall Street Zen upgraded Inovio Pharmaceuticals from “Sell” to “Hold,” while analyst opinions remained mixed. MarketBeat reports a “Moderate Buy” consensus and an average price target of $3.17.
• INO shares opened at $1.09, with a 52-week range of $0.56 to $2.98 and a market capitalization of approximately $112.7 million. The company reported quarterly EPS of negative $0.07, beating the consensus estimate of negative $0.22.
• Several institutional investors increased their positions, including JPMorgan Chase, Jane Street and Mirae Asset; institutional investors collectively own 26.79% of the stock.

Inovio Pharmaceuticals (NASDAQ:INO - Get Free Report) was upgraded by Wall Street Zen from a "sell" rating to a "hold" rating in a note issued to investors on Saturday.

Other equities analysts have also issued research reports about the company. Piper Sandler reiterated an "overweight" rating and set a $4.00 target price on shares of Inovio Pharmaceuticals in a research note on Monday, August 3rd. Weiss Ratings downgraded Inovio Pharmaceuticals from a "sell (d-)" rating to a "sell (e+)" rating in a research note on Thursday. Zacks Research raised Inovio Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a report on Wednesday. HC Wainwright reiterated a "neutral" rating on shares of Inovio Pharmaceuticals in a research report on Thursday. Finally, Jefferies Financial Group upgraded Inovio Pharmaceuticals from a "hold" rating to a "positive" rating and increased their price objective for the stock from $1.80 to $3.00 in a research report on Thursday. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat, Inovio Pharmaceuticals presently has a consensus rating of "Moderate Buy" and an average target price of $3.17.

Inovio Pharmaceuticals Stock Performance

Shares of INO opened at $1.09 on Friday. The firm has a market cap of $112.71 million, a P/E ratio of -1.20 and a beta of 1.52. Inovio Pharmaceuticals has a 52 week low of $0.56 and a 52 week high of $2.98. The firm's 50-day simple moving average is $1.03 and its 200 day simple moving average is $1.30.

Inovio Pharmaceuticals (NASDAQ:INO - Get Free Report) last issued its quarterly earnings data on Wednesday, August 12th. The biopharmaceutical company reported ($0.07) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.22) by $0.15. As a group, equities analysts forecast that Inovio Pharmaceuticals will post -0.99 earnings per share for the current year.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in INO. AQR Capital Management LLC acquired a new stake in shares of Inovio Pharmaceuticals in the first quarter valued at approximately $120,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in Inovio Pharmaceuticals by 39.6% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 20,781 shares of the biopharmaceutical company's stock worth $34,000 after acquiring an additional 5,894 shares during the period. Qube Research & Technologies Ltd bought a new position in Inovio Pharmaceuticals during the 2nd quarter worth $234,000. Jane Street Group LLC increased its stake in Inovio Pharmaceuticals by 221.2% during the 2nd quarter. Jane Street Group LLC now owns 39,683 shares of the biopharmaceutical company's stock worth $81,000 after acquiring an additional 27,329 shares during the period. Finally, JPMorgan Chase & Co. raised its holdings in Inovio Pharmaceuticals by 1,667.1% in the 3rd quarter. JPMorgan Chase & Co. now owns 65,206 shares of the biopharmaceutical company's stock valued at $153,000 after acquiring an additional 61,516 shares in the last quarter. 26.79% of the stock is owned by institutional investors.

About Inovio Pharmaceuticals

Inovio Pharmaceuticals is a biotechnology company focused on the discovery, development and commercialization of DNA-based immunotherapies and vaccines aimed at treating and preventing infectious diseases and cancers. The company leverages proprietary technologies to design synthetic DNA sequences that encode antigens capable of eliciting targeted immune responses. Inovio's business activities span early research through clinical development, with a primary emphasis on advancing candidates against viral pathogens such as SARS-CoV-2, human papillomavirus (HPV), HIV, Ebola, Zika and other emerging threats.

Central to Inovio's platform is its SynCon® technology, which constructs optimized DNA plasmids for broad antigen coverage, and the Cellectra® electroporation device, designed to enhance cellular uptake and expression of DNA vaccines.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source